Form 4 for HAE HAEMONETICS CORP
Accepted 2026-07-28 16:56:30 ET · period of report 2026-07-24 · accession 0000313143-26-000105 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-28 16:56 | 2026-07-24 | HAE | Johnson Lloyd Emerson | Dir | A - Grant | — | +2,538 | 15.5K | +20% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-24 | A | A | 2,538 | — | 15,471 | D | — | — | (F1) The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. (F2) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |